Asthma Research in the United States Right Now
The landscape of asthma research in the U.S. has shifted noticeably over the past few years. The National Heart, Lung, and Blood Institute (NHLBI), along with the National Institute of Allergy and Infectious Diseases (NIAID), continue to fund dozens of studies across the country. At the same time, pharmaceutical companies and academic medical centers are running trials that range from early safety testing to large-scale comparisons of already-approved medications.
Some of the most active research hubs include Duke University's Asthma, Allergy, and Airway Center in North Carolina, the University of Michigan's pulmonary division, Boston Children's Hospital, and the NIH Clinical Center in Bethesda, Maryland. But you do not need to live near a major academic hospital to participate. Many trials now use decentralized or hybrid models, where some study visits happen through telemedicine and medications are shipped directly to participants. The BATURA study, for instance, was designed as a fully decentralized trial testing an as-needed albuterol-budesonide inhaler in people with mild asthma, with participants completing much of the study from home.
What drives this research forward? A stubborn reality: despite widely available controller medications, a significant portion of people with asthma continue to experience flare-ups, emergency visits, and diminished quality of life. The CHRONICLE study, a large observational registry sponsored by AstraZeneca, has been tracking treatment patterns and health outcomes among individuals with severe asthma across the United States, revealing just how much variation exists in how patients respond to different therapies. This kind of real-world data helps researchers design smarter trials.
The Types of Trials You Might Encounter
Not all asthma trials are created equal, and understanding the landscape helps you decide what might fit your situation. Here is a breakdown of the main categories:
| Trial Type | What It Studies | Typical Duration | Who It May Suit | Key Considerations |
|---|
| Biologic Therapy Trials | Monoclonal antibodies targeting specific inflammatory pathways (e.g., dupilumab, benralizumab, mepolizumab) | 6 months to 2 years | People with moderate-to-severe eosinophilic or allergic asthma | Often requires regular injections; may reduce oral steroid dependence |
| Combination Inhaler Trials | Fixed-dose combinations of ICS and rescue medications | 3 to 12 months | Those with mild-to-moderate persistent asthma | Usually compares new combination against existing standard of care |
| Self-Management & Behavioral Trials | Education programs, mobile app interventions, inhaler technique training | 3 to 6 months | Broad asthma population | Lower medical risk; often remote participation possible |
| Pediatric Prevention Trials | Whether early intervention (e.g., omalizumab) can prevent asthma progression in young children with wheezing | 2 to 4 years | Children ages 2-4 with recurrent wheezing and allergies | Long commitment; parents must be highly involved |
| Observational Registries | Tracking real-world treatment patterns without changing your current medication | 1 to 5 years | Anyone with diagnosed asthma | No experimental treatment; contributes to broader scientific knowledge |
The SOLAIRIA-2 trial, currently recruiting across multiple U.S. sites, is investigating GB-0895, an investigational biologic for adolescents and adults with severe uncontrolled asthma despite using inhaled corticosteroids and other controller medications. Meanwhile, the EPIPHANY study at the University of Pennsylvania takes a different approach, using pharmacogenomics to understand why certain patients respond to specific biologics while others do not.
It is worth noting that many trials involve a placebo group, meaning some participants receive the experimental treatment while others receive a standard therapy or inactive substance. This is not something researchers hide: the informed consent process spells out exactly what the chances are of receiving the active treatment, and you can withdraw from a trial at any point.
Finding a Trial and Getting Through the Door
ClinicalTrials.gov remains the most comprehensive database, with filters that let you search by condition, location, and trial phase. The American Lung Association also maintains a network of Airways Clinical Research Centers across the country, with sites in cities like Houston, New York, and Birmingham. These centers often run trials that are designed with patient input and focus on practical questions that matter to everyday life.
But finding a trial is only the first step. Every study has inclusion and exclusion criteria that determine who can participate. A trial testing a new biologic for severe eosinophilic asthma, for example, might require a blood eosinophil count above a certain threshold and a history of at least two exacerbations in the past year despite using high-dose inhaled corticosteroids. Another trial focused on mild asthma might exclude current smokers or anyone with a recent respiratory infection.
The screening process typically involves a phone call or online questionnaire followed by an in-person visit where you undergo lung function tests, blood work, and a review of your medical history. Some trials also require a bronchoscopy, where a thin tube is inserted through the nose or mouth to collect samples from the airways. This sounds intimidating, and it is not for everyone, but research centers that perform these procedures regularly have refined their techniques to minimize discomfort.
Compensation varies widely. A study at UNC-Chapel Hill examining airway responses in people with mild asthma offered approximately $475 for completing the study procedures. Boston Children's Hospital has listed compensation of up to $2,560 in gift cards over a four-year pediatric asthma prevention trial, prorated across clinic visits and phone calls. Many trials also cover travel costs and provide study-related medical care at no charge to participants. The key is to ask about compensation during the screening call so you know what to expect before committing.
What It Actually Feels Like to Participate
The experience of being in a trial is often more structured than regular medical care. Participants typically keep daily symptom diaries, record peak flow measurements twice a day, and attend regular study visits that can range from monthly injection appointments to quarterly comprehensive evaluations. The level of monitoring is intensive, and for some people, this alone is a benefit: you get a level of attention to your asthma that is hard to replicate in a busy clinical practice.
One participant in a biologic trial described the support this way: "The whole team, the doctors and nurses, are very helpful. You can always ask them any questions at any time." She also noted that after months in the study, she could walk to the end of her street without losing her breath, something that had been out of reach before.
The risks deserve honest attention. An experimental drug might cause side effects that are not yet documented. Injection-site reactions, headaches, and transient fatigue are among the more common complaints in biologic trials. More serious adverse events, while rare, can occur. The trial team is required to report these to an institutional review board and, in some cases, to a data safety monitoring board that can halt a study if the risk profile becomes concerning.
There is also the possibility that the treatment simply does not work for you. Even in trials where the overall results are positive, individual responses vary. Some people see dramatic improvement; others notice little change. This uncertainty is part of the deal, and it is why researchers emphasize that trials are not a replacement for standard care but a complement to it.
Making Your Decision
If you are considering a clinical trial, start by talking to your current asthma specialist. They can help you assess whether your asthma is truly uncontrolled on your existing regimen and whether a trial makes sense given your specific type of asthma. Not every pulmonologist is plugged into the research world, but many are, and they can point you toward studies that are actively recruiting.
Ask the study coordinator detailed questions before you sign anything: How many visits are required? What happens if my asthma worsens during the trial? Will I have access to the study medication after the trial ends? What are my options if I am assigned to the placebo group? The informed consent document covers much of this, but a conversation with a real person often clarifies what the document cannot.
The decision to join a trial is personal. It involves weighing the inconvenience of extra appointments against the possibility of accessing a treatment that might work better than what you have now. It means accepting uncertainty while also contributing to knowledge that could help millions of other people with asthma. For those who have exhausted standard options, or for those who simply want to be part of advancing asthma care, clinical trials represent a path worth exploring.
研究の知恵